IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woodward, L. A.
Right arrow Articles by Oguma, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woodward, L. A.
Right arrow Articles by Oguma, K.

 Previous Article  |  Next Article 

Infection and Immunity, May 2003, p. 2941-2944, Vol. 71, No. 5
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.5.2941-2944.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Expression of HC Subunits from Clostridium botulinum Types C and D and Their Evaluation as Candidate Vaccine Antigens in Mice

L. A. Woodward,1,2* H. Arimitsu,2 R. Hirst,1 and K. Oguma2

Department of Microbiology and Immunology, James Cook University, Townsville 4811, Australia,1 Department of Bacteriology, Graduate School of Medicine and Dentistry, Okayama University, Okayama 700-8558, Japan2

Received 24 October 2002/ Returned for modification 22 November 2002/ Accepted 29 January 2003

Two proteins representing the heavy-chain subunits of botulinum neurotoxin types C and D were expressed in Escherichia coli, and their vaccine potential was evaluated. Mice were vaccinated with doses ranging from 0.5 to 10 µg and were challenged with 10 to 105 50% lethal doses of toxin. For the type C subunit protein, C50, two doses of 2 µg were required for full protection, while, for type D subunit protein, D50, two 1-µg doses were required. A bivalent vaccine consisting of a mixture of these two proteins also provided protection against both botulinum neurotoxin type C and type D challenge. Antibody levels in serum were determined by both enzyme-linked immunosorbent assays and serum neutralization assays

* Corresponding author. Present address: Advanced Analytical Centre, James Cook University, Townsville 4811, Australia. Phone: (61) 7 4781 6138. Fax: (61) 7 4781 5550. E-mail: lynn.woodward{at}jcu.edu.au.

Editor: J. T. Barbieri

Infection and Immunity, May 2003, p. 2941-2944, Vol. 71, No. 5
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.5.2941-2944.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2003 by the American Society for Microbiology. All rights reserved.